Latest renal osteodystrophy Stories
Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage
NEW YORK, May 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
DUBLIN, October 7 /PRNewswire-FirstCall/ -- - For Medical and Healthcare Media Only - - Direct Comparison of the Two non-Calcium Phosphate Binders Gives new Insights Into Relative Efficacy Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and...
NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
Medical Reference and Online Edition Gives Coverage of Bone and Mineral Diseases and Disorders with New International Drug Formulary WASHINGTON, Dec.
HAYWARD, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Acologix, Inc., a privately held biopharmaceutical company, will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease.
MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ -- Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S.
- The parings of haberdine; also, any kind of fragments.